June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Alterations in Circulating Leukocyte Populations in Diabetic Retinopathy
Author Affiliations & Notes
  • Gideon Obasanmi
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, Antrim, United Kingdom
  • Nuala-Jane Lavery
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, Antrim, United Kingdom
  • Jose Romero Hombrebueno
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, Antrim, United Kingdom
  • Aisling Lynch
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, Antrim, United Kingdom
  • Mei Chen
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, Antrim, United Kingdom
  • David Armstrong
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, Antrim, United Kingdom
  • Noemi Lois
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, Antrim, United Kingdom
  • Heping Xu
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, Antrim, United Kingdom
  • Footnotes
    Commercial Relationships   Gideon Obasanmi, None; Nuala-Jane Lavery, None; Jose Hombrebueno, None; Aisling Lynch, None; Mei Chen, None; David Armstrong, None; Noemi Lois, None; Heping Xu, None
  • Footnotes
    Support  JDRF Grant: JDRF 2-SRA-2014-141-Q-R
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2506. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Gideon Obasanmi, Nuala-Jane Lavery, Jose Romero Hombrebueno, Aisling Lynch, Mei Chen, David Armstrong, Noemi Lois, Heping Xu; Alterations in Circulating Leukocyte Populations in Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2506.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic retinopathy (DR) is the highest cause of blindness in the global working population. Inflammation is highly implicated in DR pathogenesis although the underlying mechanism remains poorly-defined. The aim of this study was to investigate the immunophenotype of circulating leukocytes in DR patients.

Methods : Peripheral whole blood was collected from 13 healthy controls (age-, gender-matched) and 39 type 1 DR patients, including 13 mild non-proliferative DR (NPDR), 14 non-active PDR (naPDR) and 12 active PDR (aPDR). Immunophenotype was examined by flow cytometry. The immune markers investigated in this study include lymphocytes (CD4 and CD8 T cells, CD19 B cells), monocytes (CD14++CD16-, CD14++CD16+ and CD14+CD16++); neutrophils (CD16+HLA-DR-) and NK cells (CD56); chemokine receptor expression (CCR2 and CCR5); cell adhesion molecules (CD66a and CD157); inhibitory molecule (CD305); angiogenesis marker (TIE2) and cell activation markers (HLA-DR, CD62L).

Results : The percentages of lymphocytes (CD4+, CD8+, CD19+), non-classical monocytes (CD14+CD16++), and HLA-DR+ cells were significantly reduced, and the percentage of neutrophils (CD16hiHLADR-) was significantly increased in DR compared to those in healthy controls. CD4+ cells from DR patients also expressed significantly lower levels of CD66a and CD157. The neutrophil-lymphocyte ratio (NLR), in particular, the CD16hiHLADR-/CD4+ and CD16hiHLADR-/CD19+ ratio was significantly higher in DR compared to that in healthy controls. The reduction in CD4 and CD8 T cells and the increment in CD16hiHLADR- neutrophils appear to be associated with the severity of DR, i.e., the orders of CD4% and CD8% T cells were aPDR<NPDR<Control, and the percentage of CD16hiHLADR- neutrophils was aPDR>NPDR>Control. There were no significant differences between the percentages of classical (CD14++CD16-) and intermediate (CD14++CD16+) monocytes as well as populations positive for CD56, CCR2, CCR5, CD66a, CD305, TIE2 and CD62L between DR and controls.

Conclusions : Our results suggest that DR in type-1 diabetes may be related to increased innate immunity and reduced adaptive immunity and the neutrophil/CD4 ratio may be a useful marker to predict the severity or progression of DR. Further understanding the functional alterations of the immune cells may uncover the immune mechanisms of DR and identify potential targets for therapy.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×